148 related articles for article (PubMed ID: 92978)
1. [Excretion of urinary hydroxyproline in urinary tract diseases].
Guarino A; Comar OB; Taccone W; Cicalese V
Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
[TBL] [Abstract][Full Text] [Related]
2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
3. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
[No Abstract] [Full Text] [Related]
4. [Cholesterol and urinary tract diseases].
Frick J; Spiteller G
Z Urol Nephrol; 1968 Dec; 61(12):833-8. PubMed ID: 4183283
[No Abstract] [Full Text] [Related]
5. On the origin of lactic dehydrogenase isoenzymes in urine.
Dubach UC
Helv Med Acta; 1966 Jun; 33(2):139-50. PubMed ID: 4164323
[No Abstract] [Full Text] [Related]
6. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
[No Abstract] [Full Text] [Related]
7. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
[TBL] [Abstract][Full Text] [Related]
8. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
[TBL] [Abstract][Full Text] [Related]
9. Urinary tissue factor levels in patients with bladder and prostate cancer.
Lwaleed BA; Francis JL; Chisholm M
Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyproline excretion in malignant neoplastic disease.
Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
[No Abstract] [Full Text] [Related]
11. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
Rinsho K; Aoyagi K
Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of cholesterol excretion in the urine].
Jüngst D; Osterholzer M; Lazik E; Karl HJ
Acta Med Austriaca Suppl; 1979; 6():406-9. PubMed ID: 299242
[TBL] [Abstract][Full Text] [Related]
13. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
Stĕpán JJ; Mikulecký M; Bek V; Broulík P; Pacovský V
Neoplasma; 1989; 36(4):495-501. PubMed ID: 2770935
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
15. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
Ditzel J; Jordal R; Riskoer N
Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
[No Abstract] [Full Text] [Related]
16. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Niell HB; Palmieri GM; Neely CL; McDonald MW
Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
[TBL] [Abstract][Full Text] [Related]
17. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
[TBL] [Abstract][Full Text] [Related]
18. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
[TBL] [Abstract][Full Text] [Related]
19. Study of hydroxyproline excretion in patients with prostatic cancer.
Romics I; Budavári I; Kisbenedek L; Balogh F
Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
[TBL] [Abstract][Full Text] [Related]
20. Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
Niell HB; Palmieri GM; Neely CL; Maxwell TA; Hopkins SC; Soloway MS
Arch Intern Med; 1983 Oct; 143(10):1925-7. PubMed ID: 6625779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
